((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies

European Journal of Medicinal Chemistry

Volumn 145, Issue , 2018, Pages 649-660

  Liu, Sha ^a   Jing, Li ^a   Yu, Zhu Jun ^a   Wu, Chengyong ^b   Zheng, Yongxiang ^a   Zhang, En ^c   Chen, Qiang ^b   Yu, Yamei ^b   Guo, Li ^a   Wu, Yong ^a   Li, Guo Bo ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Antibacterial resistance; Crystallography; Inhibitor design; Metallo lactamase (MBL); VIM 2

Indexed keywords

2 (4 FLUOROPHENYL) 2 ( 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID; 2 (4 HYDROXYPHENYL) 2 ( 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID; 2 BENZYL ( 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID; 2 PHENYL 2 ( 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID; 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID DERIVATIVE; 4 HYDROXYBENZYL ( 3 MERCAPTO 2 METHYLPROPANAMIDO)ACETIC ACID; ACETIC ACID DERIVATIVE; BETA LACTAMASE INHIBITOR; MEROPENEM; METALLO BETA LACTAMASE; NEW DELHI METALLO BETA LACTAMASE; UNCLASSIFIED DRUG; VERONA INTEGRON METALLO BETA LACTAMASE; ZINC ION; BETA LACTAMASE; BETA-LACTAMASE NDM-1; VIM-2 BETA-LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BROTH DILUTION; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTALLIZATION; CYTOTOXICITY ASSAY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENZYME KINETIC ASSAY; ENZYME KINETICS; ESCHERICHIA COLI; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; TRANSGENIC ZEBRAFISH; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; KINETICS; METABOLISM; MOLECULAR MODEL; SYNTHESIS; ZEBRA FISH;

ACETATES; ANIMALS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; ZEBRAFISH;

EID: 85041623585     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2018.01.032     Document Type: Article

References (57)

1. Garber, K., A β-lactamase inhibitor revival provides new hope for old antibiotics. Nat. Rev. Drug Discov. 14 (2015), 445–447.
2. Brown, D., Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?. Nat. Rev. Drug Discov. 14 (2015), 821–832.
3. Cornaglia, G., Giamarellou, H., Rossolini, G.M., Metallo-β-lactamases: a last frontier for β-lactams?. Lancet Infect. Dis. 11 (2011), 381–393.
4. Bush, K., Jacoby, G.A., Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54 (2010), 969–976.
5. Crowder, M.W., Spencer, J., Vila, A.J., Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39 (2006), 721–728.
6. Drawz, S.M., Bonomo, R.A., Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23 (2010), 160–201.
7. Wang, D.Y., Abboud, M.I., Markoulides, M.S., Brem, J., Schofield, C.J., The road to avibactam: the first clinically useful non-beta-lactam working somewhat like a beta-lactam. Future Med. Chem. 8 (2016), 1063–1084.
8. Abboud, M.I., Hinchliffe, P., Brem, J., Macsics, R., Pfeffer, I., Makena, A., Umland, K.-D., Rydzik, A.M., Li, G.-B., Spencer, J., Claridge, T.D.W., Schofield, C.J., 19F-NMR reveals the role of mobile loops in product and inhibitor binding by the são paulo metallo-β-lactamase. Angew. Chem. Int. Ed. 56 (2017), 3862–3866.
9. van Berkel, S.S., Brem, J., Rydzik, A.M., Salimraj, R., Cain, R., Verma, A., Owens, R.J., Fishwick, C.W., Spencer, J., Schofield, C.J., Assay platform for clinically relevant metallo-beta-lactamases. J. Med. Chem. 56 (2013), 6945–6953.
10. King, D.T., Strynadka, N.C., Targeting metallo-β-lactamase enzymes in antibiotic resistance. Future Med. Chem. 5 (2013), 1243–1263.
11. Brem, J., van Berkel, S.S., Aik, W., Rydzik, A.M., Avison, M.B., Pettinati, I., Umland, K.-D., Kawamura, A., Spencer, J., Claridge, T.D., McDonough, M.A., Schofield, C.J., Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem. 6 (2014), 1084–1090.
12. Cornaglia, G., Rossolini, G.M., The emerging threat of acquired carbapenemases in Gram-negative bacteria. Clin. Microbiol. Infect. 16 (2010), 99–101.
13. Bush, K., A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. Antimicrob. Agents 46 (2015), 483–493.
14. Maltezou, H.C., Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?. Int. J. Antimicrob. Agents, 33, 2009, 405 e401-407.
15. Bush, K., Evolution of β-lactamases: past, present, and future. Dougherty, T., Pucci, M., (eds.) Antibiotic Discovery and Development, 2012, Springer, Boston, MA.
16. Miraula, M., Schenk, G., Mitic, N., Promiscuous metallo-beta-lactamases: MIM-1 and MIM-2 may play an essential role in quorum sensing networks. J. Inorg. Biochem. 162 (2016), 366–375.
17. Pedroso, M.M., Selleck, C., Enculescu, C., Harmer, J.R., Mitic, N., Craig, W.R., Helweh, W., Hugenholtz, P., Tyson, G.W., Tierney, D.L., Larrabee, J.A., Schenk, G., Characterization of a highly efficient antibiotic-degrading metallo-beta-lactamase obtained from an uncultured member of a permafrost community. Metallomics 9 (2017), 1157–1168.
18. McGeary, R.P., Tan, D.T.C., Schenk, G., Progress toward inhibitors of metallo-β-lactamases. Future Med. Chem. 9 (2017), 673–691.
19. Hou, C.-F.D., Phelan, E.K., Miraula, M., Ollis, D.L., Schenk, G., N.a. Miti?, Unusual metallo-β-lactamases may constitute a new subgroup in this family of enzymes. Am. J. Mol. Biol., 4, 2014, 5.
20. Vella, P., Miraula, M., Phelan, E., Leung, E.W., Ely, F., Ollis, D.L., McGeary, R.P., Schenk, G., Mitic, N., Identification and characterization of an unusual metallo-beta-lactamase from Serratia proteamaculans. J. Biol. Inorg. Chem. 18 (2013), 855–863.
21. Mitic, et al. Christov, C.Z., (eds.) Advances in Protein Chemistry and Structural Biology: Metal-containing Enzymes, vol. 97, 2014, Elsevier, Oxford, 49.
22. Hinchliffe, P., Gonzalez, M.M., Mojica, M.F., Gonzalez, J.M., Castillo, V., Saiz, C., Kosmopoulou, M., Tooke, C.L., Llarrull, L.I., Mahler, G., Bonomo, R.A., Vila, A.J., Spencer, J., Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes. Proc. Natl. Acad. Sci. U. S. A 113 (2016), E3745–E3754.
23. Brem, J., van Berkel, S.S., Zollman, D., Lee, S.Y., Gileadi, O., McHugh, P.J., Walsh, T.R., McDonough, M.A., Schofield, C.J., Structural basis of metallo-β-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother. 60 (2016), 142–150.
24. Skagseth, S., Akhter, S., Paulsen, M.H., Muhammad, Z., Lauksund, S., Samuelsen, Ø., Leiros, H.-K.S., Bayer, A., Metallo-β-lactamase inhibitors by bioisosteric replacement: preparation, activity and binding. Eur. J. Med. Chem. 135 (2017), 159–173.
25. Arjomandi, O.K., Hussein, W.M., Vella, P., Yusof, Y., Sidjabat, H.E., Schenk, G., McGeary, R.P., Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-β-lactamase IMP-1. Eur. J. Med. Chem. 114 (2016), 318–327.
26. King, A.M., Reid-Yu, S.A., Wang, W., King, D.T., De Pascale, G., Strynadka, N.C., Walsh, T.R., Coombes, B.K., Wright, G.D., Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510 (2014), 503–506.
27. Christopeit, T., Carlsen, T.J.O., Helland, R., Leiros, H.-K.S., Discovery of novel inhibitor scaffolds against the metallo-β-lactamase VIM-2 by surface plasmon resonance (SPR) based fragment screening. J. Med. Chem. 58 (2015), 8671–8682.
28. Zhai, L., Zhang, Y.L., Kang, J.S., Oelschlaeger, P., Xiao, L., Nie, S.S., Yang, K.W., Triazolylthioacetamide: a valid scaffold for the development of New Delhi metallo-beta-lactmase-1 (NDM-1) inhibitors. ACS Med. Chem. Lett. 7 (2016), 413–417.
29. Brem, J., Cain, R., Cahill, S., McDonough, M.A., Clifton, I.J., Jiménez-Castellanos, J.-C., Avison, M.B., Spencer, J., Fishwick, C.W.G., Schofield, C.J., Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 7 (2016), 12406–12413.
30. Cahill, S.T., Cain, R., Wang, D.Y., Lohans, C.T., Wareham, D.W., Oswin, H.P., Mohammed, J., Spencer, J., Fishwick, C.W.G., McDonough, M.A., Schofield, C.J., Brem, J., Cyclic boronates inhibit all classes of β-lactamase. Antimicrob. Agents Chemother., 61, 2017, e02260-02216.
31. McGeary, R.P., Tan, D.T.C., Selleck, C., Monteiro Pedroso, M., Sidjabat, H.E., Schenk, G., Structure-activity relationship study and optimisation of 2-aminopyrrole-1-benzyl-4,5-diphenyl-1H-pyrrole-3-carbonitrile as a broad spectrum metallo-β-lactamase inhibitor. Eur. J. Med. Chem. 137 (2017), 351–364.
32. Vella, P., Hussein, W.M., Leung, E.W., Clayton, D., Ollis, D.L., Mitić, N., Schenk, G., McGeary, R.P., The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. Bioorg. Med. Chem. Lett. 21 (2011), 3282–3285.
33. Mohamed, M.S., Hussein, W.M., McGeary, R.P., Vella, P., Schenk, G., Abd El-Hameed, R.H., Synthesis and kinetic testing of new inhibitors for a metallo-β-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Eur. J. Med. Chem. 46 (2011), 6075–6082.
34. Faridoon, W.M., Hussein, P., Vella, N.U., Islam, D.L., Ollis, G., Schenk, R.P., McGeary, 3-mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-beta-lactamase inhibitors. Bioorg. Med. Chem. Lett 22 (2012), 380–386.
35. Hussein, W.M., Fatahala, S.S., Mohamed, Z.M., McGeary, R.P., Schenk, G., Ollis, D.L., Mohamed, M.S., Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-β-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Chem. Biol. Drug Des. 80 (2012), 500–515.
36. Sevaille, L., Gavara, L., Bebrone, C., De Luca, F., Nauton, L., Achard, M., Mercuri, P., Tanfoni, S., Borgianni, L., Guyon, C., Lonjon, P., Turan-Zitouni, G., Dzieciolowski, J., Becker, K., Benard, L., Condon, C., Maillard, L., Martinez, J., Frere, J.M., Dideberg, O., Galleni, M., Docquier, J.D., Hernandez, J.F., 1,2,4-Triazole-3-thione compounds as inhibitors of di-zinc metallo-beta-lactamases. ChemMedChem 12 (2017), 972–985.
37. Li, G.-B., Abboud, M.I., Brem, J., Someya, H., Lohans, C.T., Yang, S.-Y., Spencer, J., Wareham, D.W., McDonough, M.A., Schofield, C.J., NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. Chem. Sci. 8 (2017), 928–937.
38. Li, G.-B., Brem, J., Lesniak, R., Abboud, M.I., Lohans, C.T., Clifton, I.J., Yang, S.-Y., Jimenez-Castellanos, J.-C., Avison, M.B., Spencer, J., McDonough, M.A., Schofield, C.J., Crystallographic analyses of isoquinoline complexes reveal a new mode of metallo-β-lactamase inhibition. Chem. Commun. 53 (2017), 5806–5809.
39. Yusof, Y., Tan, D.T.C., Arjomandi, O.K., Schenk, G., McGeary, R.P., Captopril analogues as metallo-beta-lactamase inhibitors. Bioorg. Med. Chem. Lett 26 (2016), 1589–1593.
40. Li, G.-B., Ji, S., Yang, L.-L., Zhang, R.-J., Chen, K., Zhong, L., Ma, S., Yang, S.-Y., LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. Eur. J. Med. Chem. 93 (2015), 523–538.
41. Tetko, I.V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin, V.A., Radchenko, E.V., Zefirov, N.S., Makarenko, A.S., Tanchuk, V.Y., Prokopenko, V.V., Virtual computational chemistry laboratory–design and description. J. Comput. Aided Mol. Des. 19 (2005), 453–463.
42. Ebejer, J.P., Charlton, M.H., Finn, P.W., Are the physicochemical properties of antibacterial compounds really different from other drugs?. J. Cheminf., 8, 2016, 30.
43. Brown, D.G., May-Dracka, T.L., Gagnon, M.M., Tommasi, R., Trends and exceptions of physical properties on antibacterial activity for gram-positive and gram-negative pathogens. J. Med. Chem. 57 (2014), 10144–10161.
44. Shoichet, B.K., Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 49 (2006), 7274–7277.
45. Copeland, R.A., Evaluation of Enzyme Inhibitors in Drug Discovery. 2013, Wiley.
46. King, D.T., Worrall, L.J., Gruninger, R., Strynadka, N.C.J., New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition. J. Am. Chem. Soc. 134 (2012), 11362–11365.
47. Feng, H., Ding, J., Zhu, D., Liu, X., Xu, X., Zhang, Y., Zang, S., Wang, D.C., Liu, W., Structural and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins. J. Am. Chem. Soc. 136 (2014), 14694–14697.
48. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., McCoy, A.J., Moriarty, N.W., Oeffner, R., Read, R.J., Richardson, D.C., Richardson, J.S., Terwilliger, T.C., Zwart, P.H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr 66 (2010), 213–221.
49. Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr 60 (2004), 2126–2132.
50. Trott, O., Olson, A.J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2010), 455–461.
51. Li, G.-B., Yu, Z.-J., Liu, S., Huang, L.-Y., Yang, L.-L., Lohans, C.T., Yang, S.-Y., IFPTarget: a customized virtual target identification method based on protein–ligand interaction fingerprinting analyses. J. Chem. Inf. Model. 57 (2017), 1640–1651.
52. Li, G.-B., Yang, L.-L., Wang, W.-J., Li, L.-L., Yang, S.-Y., ID-score: a new empirical scoring function based on a comprehensive set of descriptors related to protein–ligand interactions. J. Chem. Inf. Model. 53 (2013), 592–600.
53. Wang, H.-L., Liu, S., Yu, Z.-J., Wu, C., Cheng, L., Wang, Y., Chen, K., Zhou, S., Chen, Q., Yu, Y., Li, G.-B., Interactions between sirtuins and fluorogenic small-molecule substrates offer insights into inhibitor design. RSC Adv. 7 (2017), 36214–36222.
54. CLSI M07-A10, 2 ed., Clinical and Laboratory Standards Institute, Wayne, PA, U.S., 2015, Vol. 35.
55. Liu, X.-L., Shi, Y., Kang, J.S., Oelschlaeger, P., Yang, K.-W., Amino acid thioester derivatives: a highly promising scaffold for the development of metallo-β-lactamase L1 inhibitors. ACS Med. Chem. Lett. 6 (2015), 660–664.
56. Yang, L.-L., Li, G.-B., Ma, S., Zou, C., Zhou, S., Sun, Q.-Z., Cheng, C., Chen, X., Wang, L.-J., Feng, S., Li, L.-L., Yang, S.-Y., Structure–activity relationship studies of pyrazolo [3, 4-d] pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo. J. Med. Chem. 56 (2013), 1641–1655.
57. Chen, X., Ji, P., Yang, H.-W., Yang, L.-L., Zhou, S., Zhong, L., Ma, S., Fu, X.-Y., Zhou, C., Li, G.-B., Zheng, M.-W., Wei, Y.-Q., Yang, S.-Y., SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models. Cell. Physiol. Biochem. 32 (2013), 138–153.